Sanofi

Genzyme Corporation

Rao Koduri

Kevin Brower

Marcella Yu

Huawei Qiu

Patrick Finn

Christopher Winter

Joachim Theilhaber

Richard C Gregory

Parminder Mankoo

Jack R Pollard

Gary Shapiro

Natalia Malkova

Feng Song Liu

Konstantin Konstantinov

Veena Warikoo

Christopher Hwang

Jin Yin

Feng Liu

Chris Hwang

Kevin P Brower

The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Anti-TGF-beta antibodies and their use

The invention provides an improved pan-TGF-&#x3b2; antibody for treatment of conditions that are mediated by TGF-&#x3b2;, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Anti-TGF-&#x3b2; antibodies and their use

Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution.

Methods of controlling the formation of disulfide bonds in protein solutions

Growing community of inventors

Shrewsbury, MA, United States of America

Rao Koduri